Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10272087" target="_blank" >RIV/00216208:11110/14:10272087 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/14:00076233 RIV/00216208:11130/14:10272087 RIV/00216208:11140/14:10272087 RIV/61989592:15110/14:33150515 and 4 more

Result on the web

<a href="http://www.sciencedirect.com/science/article/pii/S1078143913005097#" target="_blank" >http://www.sciencedirect.com/science/article/pii/S1078143913005097#</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.urolonc.2013.12.007" target="_blank" >10.1016/j.urolonc.2013.12.007</a>

Result language

angličtina

Original language name

Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis

Original language description

Objectives: The aim of the present study was to describe the efficacy and safety of everolimus in the treatment of metastatic renal cell carcinoma (mRCC) after administration of 1 vs. 2 prior tyrosine kinase inhibitors (TKIs). Patients and methods: A national renal information system database was used as the data source for the retrospective study. There were 483 patients who received everolimus as the second (n = 350) or the third (n = 112) targeted agent following TKIs. Results: Median progression-free survival (PFS) from the start of everolimus in the second or the third line of targeted therapy was 6.1 months for both subgroups (P = 0.863). Median total PFS from the start of the first targeted agent to progression on the third targeted agent for patients receiving 3 lines of therapy with TKI-TKI-everolimus (n = 112) and TKI-everolimus-TKI (n = 27) sequences was 28.3 months vs. 31.3 months, respectively (P = 0.16), and there was no significant difference in overall survival. PFS on

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2014

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Urologic Oncology: Seminars and Original Investigations

ISSN

1078-1439

e-ISSN

—

Volume of the periodical

32

Issue of the periodical within the volume

5

Country of publishing house

US - UNITED STATES

Number of pages

7

Pages from-to

569-575

UT code for WoS article

000338090800009

EID of the result in the Scopus database

—